| Literature DB >> 35788658 |
Yeongin Jung1, Kihun Kim2, Sang Tae Choi3, Jin Mo Kang3, Noo Ree Cho4, Dai Sik Ko5, Yun Hak Kim6,7.
Abstract
The surgical workforce, like the rest of the population, is ageing. This has raised concerns about the association between the age of the surgeon and their surgical outcomes. We performed a systematic review and meta-analysis of cohort studies on postoperative mortality and major morbidity according to the surgeons' age. The search was performed on February 2021 using the Embase, Medline and CENTRAL databases. Postoperative mortality and major morbidity were evaluated as clinical outcomes. We categorized the surgeons' age into young-, middle-, and old-aged surgeons. We compared the differences in clinical outcomes for younger and older surgeons compared to middle-aged surgeons. Subgroup analyses were performed for major and minor surgery. Ten retrospective cohort studies on 29 various surgeries with 1,666,108 patients were considered. The mortality in patients undergoing surgery by old-aged surgeons was 1.14 (1.02-1.28, p = 0.02) (I2 = 80%) compared to those by middle-aged surgeon. No significant differences were observed according to the surgeon's age in the major morbidity and subgroup analyses. This meta-analysis indicated that surgeries performed by old-aged surgeons had a higher risk of postoperative mortality than those by middle-aged surgeons. Thus, it necessitates the introduction of a multidisciplinary approach to evaluate the performance of senior surgeons.Entities:
Mesh:
Year: 2022 PMID: 35788658 PMCID: PMC9252995 DOI: 10.1038/s41598-022-15275-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1The PRISMA flow diagram.
Characteristics of the studies included for the analyses.
| Study, year | Outcomes | Surgeon’s age | Types of surgery | Patients studied (n) | Nationality | Study period | Major morbidity | Adjustment | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Matar et al.[ | Unadjusted OR (morbidity) Adjusted OR (morbidity) | < 45 years (young) 45–55 years (middle) > 55 years (old) | Total hip arthroplasty | Total—122,043 Young—47,726 Middle—35,842 Old—38,475 | Canada | 2002–2018 | Composite complication | Clustering by surgeon |
| 2 | Lin et al.[ | Unadjusted OR (morbidity) | 28–41 years (young) 41–50 years (middle) 50–65 years (old) | Adenoidectomy | Total—5435 Young—3439 Middle—1522 Old—474 | Taiwan | 2002–2011 | Reoperation | |
| 3 | Tsugawa et al.[ | Unadjusted OR (mortality) Adjusted OR (mortality) | < 40 years (young) 40–49 years (middle) 50–59 years (old) ≥ 60 years (old) | Twenty major surgical procedures (16 most common non-cardiovascular surgeries in Medicare population and 4 common cardiovascular surgeries) | Total—892,187 Young—149,349 Middle—292,103 Old—450,735 | USA | 2011–2014 | Patients’ and surgeons’ characteristics and hospital fixed effects | |
| 4 | Anderson et al.[ | Unadjusted OR (morbidity) Unadjusted OR (mortality) Adjusted OR (morbidity) Adjusted OR (mortality) | < 40 years (young) 40–50 years, (middle) 50–60 years (old) > 60 years (old) | Congenital heart surgery | Total—62,851 Young—6198 Middle—29,391 Old—27,262 | USA | 2010–2014 | Major morbidity | Not specified |
| 5 | Markar et al.[ | Unadjusted OR (morbidity) Unadjusted HR (mortality) Adjusted HR (mortality) | ≤ 51 years (young) 52–55 year (middle) ≥ 56 years (old) | Esophagectomy | Total—1761 Young—946 Middle—291 Old—524 | Sweden | 1987–2010 | Reoperation | Age, sex, comorbidity, tumor stage, tumor histology, neoadjuvant therapy, surgeon volume of esophagectomies, and calendar period of surgery |
| 6 | Stevens et al.[ | Unadjusted OR (morbidity) Adjusted OR (morbidity) | 45 years (young) 45–55 years (middle) > 55 years (old) | Primary laparoscopic Roux-en-Y Gastric Bypass, sleeve gastrectomy | Total—60,430 Young—14,322 Middle—31,936 Old—14,172 | USA | 2006–2016 | Overall complication | Patient characteristics and comorbidities, and surgeon volume, years of experience, a and fellowship |
| 7 | Wu et al.[ | Unadjusted OR (morbidity) Adjusted OR (morbidity) | < 40 years (young) 40–49 year (middle) ≥ 50 years (old) | Hysteropexy and hysterectomy | Total—36,609 Young—9256 Middle—17,011 Old—10,342 | Taiwan | 1997–2010 | Repeat surgery | Not specified |
| 8 | Ho et al.[ | Unadjusted OR (morbidity) Adjusted OR (morbidity) | ≤ 40 years (young) 41–50 year (middle) ≥ 51 years (old) | Scleral bucking, pars plana vitrectomy, or both | Total—7427 Young—2994 Middle—3668 Old—765 | Taiwan | 2002–2004 | 180-day readmission | Surgeon volume, hospital volume, and hospital level |
| 9 | Waljee et al.[ | Adjusted OR (mortality) | ≤ 40 years (young) 41–50 years (middle) 51–60 years > 61 years (old) | Eight procedures (coronary artery bypass grafting, elective abdominal aneurysm repair, aortic valve replacement, carotid endarterectomy, pancreatectomy, esophagectomy, lung resection, and cystectomy) | Total—461,000 | USA | 1998–1999 | Patient and provider characteristics | |
| 10 | O’Neill et al.[ | Unadjusted OR (morbidity) Unadjusted OR (mortality) | 30–39 years (young) 40–49 years (young) 50–59 years (middle) 60–64 years (old) 65 or higher (old) | Carotid endarterectomy | Total—11,424 Young—7438 Middle—2931 Old—1055 | USA | 1994–1995 | Number of bad outcomes |
Figure 2The mortality in the patients undergoing surgery according to surgeon’s age.
Figure 3The major morbidity in the patients undergoing surgery according to surgeon’s age.
Subgroup analysis of major morbidity stratified by major and minor surgery.
| Major morbidity | Number of results | Heterogeneity (%) | Odds ratio (95% confidence interval) |
|---|---|---|---|
| Young (ref. middle) | 7 | 81 | 1.10 (0.96–1.26) |
| Old (ref. middle) | 6 | 81 | 0.96 (0.81–1.13) |
| Old (ref. young) | 7 | 92 | 0.92 (0.74–1.16) |
| Young (ref. middle) | 4 | 84 | 0.90 (0.65–1.26) |
| Old (ref. middle) | 4 | 0 | 1.20 (0.97–1.48) |
| Old (ref. young) | 4 | 21 | 1.15 (0.92–1.42) |
Quality assessment of included studies.
| Study | Selection | Comparability based on design and analysis | Outcome | Total | Assessment | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Representativeness of the sample | Selection of the non-intervention cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at the start of the study | Assessment of outcome | Was follow-up long enough for outcomes to occur | Adequacy of follow-up of cohorts | ||||
| Matar et al.[ | 1 | 1 | 1 | 1 | 1 | 1 | 6 | Poor | ||
| Lin et al.[ | 1 | 1 | 1 | 1 | 1 | 1 | 6 | Poor | ||
| Tsugawa et al.[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 8 | Good | |
| Anderson et al.[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 8 | Good | |
| Markar et al.[ | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 8 | Good | |
| Stevens et al.[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 8 | Good | |
| Wu et al.[ | 1 | 1 | 1 | 1 | 1 | 5 | Poor | |||
| Ho et al.[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Good |
| Waljee et al.[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 8 | Good | |
| O’Neill et al.[ | 1 | 1 | 1 | 1 | 1 | 5 | Poor | |||
Good quality: 3 or 4 stars in selection domain AND 1 or 2 stars in compatibility domain AND 2 or 3 stars in outcome/exposure domain, Fair quality: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain, Poor quality: 0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain.